Inventors list |
Assignees list |
Classification tree browser |
Top 100 Inventors |
Top 100 Assignees |
Bondurant
Bruce Bondurant, Durham, NC US
| Patent application number | Description | Published |
|---|---|---|
| 20090304589 | RADIATION SENSITIVE LIPOSOMES - The present invention relates to a radiation sensitive liposome, and the use of this liposome as carrier for therapeutic and diagnostic agent(s). In particular, the invention encompasses a liposome composition comprising a stable liposome-forming lipid and a polymerizable colipid, and a chain transfer agent. The present invention further contemplates methods of diagnosing and treating conditions and diseases that are responsive to liposome-encapsulated or associated agents. | 12-10-2009 |
Bruce Bondurant, Tucson, AZ US
| Patent application number | Description | Published |
|---|---|---|
| 20110217236 | RADIATION SENSITIVE LIPOSOMES - The present invention relates to a radiation sensitive liposome, and the use of this liposome as carrier for therapeutic and diagnostic agent(s). In particular, the invention encompasses a liposomal delivery system, comprising a stable liposome-forming lipid and a polymerizable colipid, a fraction of which polymerizable colipid polymerizes upon exposure to ionizing, radiation, thereby destabilizing the liposomal membrane. Destabilization of liposomes allows for leakage of liposomal contents. The present invention further contemplates methods of diagnosing and treating conditions and diseases that are responsive to liposome-encapsulated or associated agents. | 09-08-2011 |
Kristina L. Bondurant, Little Rock, AR US
| Patent application number | Description | Published |
|---|---|---|
| 20080279872 | Immunotherapeutic methods targeted toward stratum corneum chymotryptic enzyme - The present invention discloses the protease stratum corneum chymotrytic enzyme (SCCE) is specifically over-expressed in ovarian and other malignancies. A number of SCCE peptides can induce immune responses to SCCE, thereby demonstrating the potential of these peptides in monitoring and the development of immunotherapies for ovarian and other malignancies. | 11-13-2008 |
| 20110038895 | MULTI-EPITOPE PEPTIDE-LOADED DENDRITIC CELL IMMUNOTHERAPY FOR CANCER - The invention involves peptides of from about 7 to about 50 amino acid residues in length that have epitopes that bind to more than one HLA class II protein and stimulate CD4+ T cells for treatment of cancer from one of three serine proteases overexpressed in ovarian cancer and other cancers—stratum corneum chymotryptic enzyme, matriptase, and hepsin. Since the peptides bind to more than one HLA class II protein variant, they can be used to treat cancer in most patients of a population having a variety of HLA class II alleles. The peptides can be loaded onto autologous dendritic cells of a cancer patient and infused into the patient to activate a CD4+ and CD8+ T cell response that recognizes tumor cells expressing the peptide antigen. | 02-17-2011 |